Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> JAK/STAT Signaling

JAK/STAT Signaling

Targets for  JAK/STAT Signaling

Products for  JAK/STAT Signaling

  1. Cat.No. Product Name Information
  2. GC31752 Tesevatinib (XL-647)

    EXEL-7647, Tesevatinib

     Tesevatinib (XL-647) (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM. Tesevatinib (XL-647) Chemical Structure
  3. GC39022 Tetramethylcurcumin Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin Chemical Structure
  4. GC25992 TG-89 TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM. TG-89 Chemical Structure
  5. GC38081 Theliatinib Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases. Anti-tumor activity. Theliatinib Chemical Structure
  6. GC19361 TP-3654 TP-3654 is a second-generation Pim kinase inhibitor with Ki values of 5 and 42 nM for Pim-1 and Pim-3, respectively. TP-3654 Chemical Structure
  7. GC17621 TPCA-1 A selective inhibitor of IKK2 TPCA-1 Chemical Structure
  8. GC34215 Trastuzumab (Anti-Human HER2, Humanized Antibody)

    Trastuzumab is a fully humanized monoclonal antibody directed at HER2 which binds the external domain of the receptor and exerts its action via a combination of antibody-dependent cytotoxicity, reduced shedding of the extracellular domain, inhibition of dimerization and possibly receptor downregulation.

     Trastuzumab (Anti-Human HER2, Humanized Antibody) Chemical Structure
  9. GC32726 Tucatinib (Irbinitinib)

    ARRY-380, ONT-380

     Tucatinib (Irbinitinib) (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib (Irbinitinib) Chemical Structure
  10. GC34847 TX1-85-1 An ErbB3 inhibitor TX1-85-1 Chemical Structure
  11. GC31668 TYK2-IN-2 TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC50s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TYK2-IN-2 Chemical Structure
  12. GC32052 Tyk2-IN-3 Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC50 of 485 nM. Tyk2-IN-3 Chemical Structure
  13. GC31659 Tyk2-IN-4 (BMS-986165)

    BMS-986165

     Tyk2-IN-4 (BMS-986165) (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Tyk2-IN-4 (BMS-986165) Chemical Structure
  14. GC65387 Tyk2-IN-5 Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Ki of 0.086 nM for Tyk2 JH2 and an IC50 of 25 nM for IFNα. Tyk2-IN-5 Chemical Structure
  15. GC37846 Tyk2-IN-7 Tyk2-IN-7 (Compound 48) is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki. Tyk2-IN-7 Chemical Structure
  16. GC37847 Tyk2-IN-8 Tyk2-IN-8 (Compound 3) is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 Chemical Structure
  17. GC19364 Tyrphostin AG 528

    Tyrphostin AG-528

     Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 uM, respectively. Tyrphostin AG 528 Chemical Structure
  18. GC15271 Tyrphostin AG 879

    Tyrphostin AG879

     HER2 inhibitor Tyrphostin AG 879 Chemical Structure
  19. GC38125 Tyrphostin AG30 Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts. Tyrphostin AG30 Chemical Structure
  20. GC19368 Upadacitinib

    ABT-494

     Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders. Upadacitinib Chemical Structure
  21. GC12249 Varlitinib (ARRY334543)

    ARRY-334543; ARRY 334543

     Varlitinib (ARRY334543) (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively. Varlitinib (ARRY334543) Chemical Structure
  22. GN10282 Vitexicarpin (Casticin)

    Vitexicarpin

     Vitexicarpin (Casticin) Chemical Structure
  23. GC67867 VVD-118313 VVD-118313 Chemical Structure
  24. GC40761 VX-509 VX-509 is a selective inhibitor of Janus kinase 3 (JAK3) with a Ki value of 2.5 nM in enzyme assays and an IC50 value of 50-170 nM in cellular assays dependent on JAK3 activity with no measurable activity against other JAK isotypes. VX-509 Chemical Structure
  25. GC70140 W1131

    W1131 is an effective STAT3 inhibitor that can induce ferroptosis. W1131 inhibits cancer progression in gastric cancer subcutaneous xenograft models, organoid models, and PDX models. W1131 effectively reduces chemoresistance of cancer cells to 5-FU. W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation pathways including the IL6-JAK-STAT3 pathway and ferroptosis pathway.

     W1131 Chemical Structure
  26. GC73420 W1131 TFA W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. W1131 TFA Chemical Structure
  27. GC16000 WHI-P180

    Janex 3

     EGFR/Janus Kinase 3 inhibitor WHI-P180 Chemical Structure
  28. GC37933 WHI-P180 hydrochloride

    Janex 3 hydrochloride;

     WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 hydrochloride Chemical Structure
  29. GC15980 WP1066

    STAT Inhibitor III

    An inhibitor of STAT3

     WP1066 Chemical Structure
  30. GC13213 WZ3146 Mutant EGFR inhibitor, potent and irreversible WZ3146 Chemical Structure
  31. GC15494 WZ4002 Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent WZ4002 Chemical Structure
  32. GC11250 WZ8040 EGFR T790M inhibitor,irreversible amd potent WZ8040 Chemical Structure
  33. GC73582 YK-029A YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A Chemical Structure
  34. GC64891 YM-341619

    AS1617612

     YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM. YM-341619 Chemical Structure
  35. GC73561 YS-363 YS-363 is a potent, selective, and orally active EGFR inhibitor, with IC50s of 0.96 nM and 0.67 nM for wild-type and L858R mutant forms of EGFR, respectively. YS-363 Chemical Structure
  36. GC73747 YS-67 YS-67 is a potent inhibitor of EGFR with an IC 50 of 5.2 nM. YS-67 Chemical Structure
  37. GC70164 Zalutumumab

    Zalutumumab is a highly affinity pure human IgG1 monoclonal antibody that targets EGFR. Zalutumumab binds to domain III of the epidermal growth factor receptor, exerting its effects by blocking the binding of epidermal growth factor and interfering with the receptor's active conformation. The EC50 values for Zalutumumab with IgG and its Fab regions are 7 and 19 nM, respectively. Zalutumumab can be used in cancer research.

     Zalutumumab Chemical Structure
  38. GC70165 Zanidatamab

    ZW 25

    Zanidatamab (ZW25) is a human bispecific monoclonal antibody targeting 2 different HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumor activity.

     Zanidatamab Chemical Structure
  39. GC33171 ZD-4190 ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer. ZD-4190 Chemical Structure
  40. GC70169 Zenocutuzumab

    MCLA-128; PB4188; R040517

     Zenocutuzumab is a bispecific humanized IgG1 antibody containing two different Fab arms that target the extracellular domains of HER2 and HER3. Zenocutuzumab Chemical Structure
  41. GC37971 ZM39923 ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM. ZM39923 Chemical Structure

Items 401 to 440 of 440 total

per page
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5

Set Descending Direction